Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer founded in 1940 and headquartered in Barcelona, Spain. The company specializes in producing blood plasma-based products, making it a global leader in this field. Grifols also supplies devices, instruments, and reagents for clinical testing laboratories. Their mission focuses on improving health and well-being worldwide through innovation and sustainability in pharmaceuticals and diagnostics.
Grifols has achieved significant financial success, with a revenue of €6.064 billion and a net income of €271.1 million in 2022. The company is publicly traded on BMAD and Nasdaq under the symbols GRF and GRFS, respectively. Key figures include CEO Nacho Abia and Chairman Thomas Glanzmann. Grifols' commitment to innovation and sustainability has positioned it as a leader in the pharmaceutical industry, impacting global health through advanced therapeutic solutions.
